This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Other Cardiac Arrhythmias기타 심장부정맥

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: I49 (Other cardiac arrhythmias) | Special Copayment Reduction: V192 (Special copayment reduction for heart disease: 5% copayment for up to 30 days from the registration date)
B. SynonymsVentricular fibrillation (VF), ventricular flutter, premature atrial contraction (PAC), premature junctional contraction (JPC), premature ventricular contraction (PVC), sick sinus syndrome (SSS), premature ventricular depolarization
C. Adult onsetPVCs occur at all ages, but their frequency increases from middle age onward. Ventricular fibrillation occurs predominantly in patients with underlying heart disease, and sick sinus syndrome mainly in the elderly aged 65 and older.
1. HistoryDescriptions of premature contractions began before the introduction of electrocardiography in the 1880s. Holter monitoring in the 1960s, electrophysiology studies in the 1970s, and the introduction of the ICD in the 1980s formed the foundation of diagnosis and treatment.
2. CausesIschemic heart disease (PVC, VF), autonomic imbalance (PAC, PVC), electrolyte abnormalities, catecholamine excess, cardiomyopathy, and sinus node dysfunction (advanced age, fibrosis) are the main causes.
3. GeneticsSCN5A, RYR2, HCN4, ANKRD1, and KCNQ1 variants are associated with inherited arrhythmias such as ventricular fibrillation and sick sinus syndrome.
4. General epidemiologyPVCs are found in about 1-4% of the general population and in 75-80% on long-term Holter monitoring. Sick sinus syndrome accounts for about 50% of pacemaker implantations.
5. PathophysiologyThree mechanisms: enhanced ectopic automaticity, reentry, and triggered activity. In sinus node dysfunction, sinoatrial node fibrosis and reduced ion channel expression are central.
6. SymptomsPVC: palpitations, skipped beats. Sinus node dysfunction: dizziness, syncope, fatigue. Ventricular fibrillation: immediate loss of consciousness (equivalent to cardiac arrest).
7. SignsPVC: wide, bizarre QRS and compensatory pause on ECG. SSS: slow or pausing pulse, sinus-AV block-sinus arrest on ECG. VF: pulselessness, loss of consciousness.
8. Screening12-lead ECG, 24-hour Holter, exercise stress test, implantable loop recorder. When PVC burden is >10%/day, echocardiography and cardiac MRI are needed to evaluate for structural heart disease.
9. DiagnosisECG-based arrhythmia classification, 24-hour Holter, EPS (provocation testing), echocardiography, cardiac MRI (evaluation of structural substrate), genetic testing.
10. TreatmentSymptomatic PVC: beta-blockers, catheter ablation. Sinus node dysfunction: pacemaker implantation. Ventricular fibrillation: ICD. Individualized treatment based on the JCS 2024 guideline.
11. PrognosisPVCs without structural heart disease are benign. Cardiac function may decline when PVC burden is >15%. Sinus node dysfunction symptoms improve with a pacemaker. VF recurrence is prevented with an ICD.
12. PreventionTreatment of underlying heart disease, maintenance of electrolyte balance, avoidance of unnecessary QT-prolonging drugs, limiting excessive alcohol and caffeine, and prevention of sudden death with an ICD.
13. ReferencesJCS/JHRS 2024 Guideline Focused Update on Management of Cardiac Arrhythmias … and 9 other papers

1. History

The category of other cardiac arrhythmias (ICD-10 I49) includes a variety of arrhythmias such as ventricular fibrillation (I49.0), premature atrial depolarization (I49.1), premature junctional depolarization (I49.2), premature ventricular depolarization (I49.3), and sick sinus syndrome (I49.5). Each of these arrhythmias has its own history of discovery, but they have commonly developed alongside electrocardiographic technology.

The clinical significance of premature ventricular contraction (PVC) began when Wenckebach described pulse deficits in the 1890s. In 1903, Einthoven first recorded the characteristic wide, bizarre QRS of PVCs on electrocardiography, and various forms of PVC (bigeminy, trigeminy, couplets, nonsustained VT, etc.) were subsequently classified systematically. In 1970, Bernard Lown published the Lown grading, which graded the complexity of PVCs, and it was applied to PVC management after myocardial infarction. However, in the 1989 CAST (Cardiac Arrhythmia Suppression Trial), antiarrhythmic drugs (flecainide, encainide, moricizine) after myocardial infarction suppressed PVCs yet paradoxically increased mortality, leading to a paradigm shift that suppression of PVCs itself does not guarantee a survival benefit.

Sick Sinus Syndrome (SSS) was formalized in 1967 when Bernard Lown named sinoatrial node dysfunction after direct-current cardioversion "sick sinus syndrome." Subsequently, with the development of permanent pacemakers in the 1970s, treatment of SSS improved dramatically. Research on the mechanism of ventricular fibrillation began with experimental studies by Moe, Garrey, and others in the 1940s-60s, and Mirowski's clinical introduction of the ICD in 1980 revolutionized the treatment of ventricular fibrillation. The 2024 JCS/JHRS guideline compiled the latest evidence on arrhythmia management.


2. Causes

The causes of arrhythmias in the I49 category vary by type. The most common cause of ventricular fibrillation (VF) is ischemic heart disease (acute myocardial infarction, chronic ischemia); other causes include nonischemic cardiomyopathy (dilated, hypertrophic, ARVC), inherited channelopathies (long QT, Brugada, CPVT), electrolyte abnormalities (hypokalemia, hypomagnesemia), and drug toxicity.

Premature ventricular contractions (PVC) also occur in healthy individuals, but causes include ischemia, cardiomyopathy, hyperthyroidism, electrolyte abnormalities (hypokalemia, hypomagnesemia), caffeine, alcohol, smoking, catecholamine excess (panic disorder, pheochromocytoma), and antiarrhythmic drug toxicity. About 10-20% of PVCs are accompanied by structural heart disease, and frequent PVCs (>10,000-15,000/day or ≥10-15% of total beats) can cause PVC-induced cardiomyopathy.

The most common cause of sick sinus syndrome (SSS) is degenerative fibrosis of the sinoatrial node and surrounding tissue, which increases markedly in the elderly (65 years and older). Other causes include ischemic heart disease (occlusion of the right coronary artery or sinoatrial nodal artery), infiltrative diseases (amyloidosis, sarcoidosis, hemochromatosis), inflammatory diseases (myocarditis, Lyme disease), drugs (beta-blockers, non-dihydropyridine calcium channel blockers, digoxin, amiodarone), and surgical injury.


3. Genetics

The genetic basis of arrhythmias in the I49 category is particularly important in idiopathic ventricular fibrillation and sick sinus syndrome. The HCN4 gene encodes the HCN4 channel that regulates the pacemaker current (If) of the sinoatrial node, and loss-of-function variants of this gene are associated with familial sinus bradycardia and sick sinus syndrome. Variants such as HCN4 D553N have been reported in idiopathic sinus node dysfunction.

Loss-of-function variants of the SCN5A gene cause various cardiac conduction diseases, including sinoatrial node conduction disorders. Gain-of-function variants of the RYR2 gene (ryanodine receptor 2) increase spontaneous calcium release upon catecholamine stimulation, inducing delayed afterdepolarizations (DAD) and PVCs; this is the molecular mechanism of CPVT progressing to ventricular fibrillation. Genes associated with idiopathic ventricular fibrillation include SCN5A, KCNJ8, CACNA1C, CALM1/2/3 (calmodulin).

Variants of the ANK2 (Ankyrin-B) gene, through abnormalities of an ion channel anchoring protein, cause a combination of sinus node dysfunction, QT prolongation, and PVCs. As a structural heart disease associated with PVCs, desmosomal gene variants such as PKP2, DSP, DSG2 are important in ARVC. When familial arrhythmia is suspected, next-generation sequencing (NGS)-based cardiac arrhythmia panel testing is performed.


4. General epidemiology

Premature ventricular contraction (PVC) is a very common arrhythmia in the general population. PVCs are found in about 1-4% on 12-lead ECG, and on 24-48-hour Holter monitoring at least one PVC is observed in about 40-75% of adults. PVC frequency of ≥1% of total beats is estimated in about 1-4% of the adult population. PVCs without structural heart disease are associated with increasing age, hypertension, excessive caffeine intake, and stress.

Sick sinus syndrome (SSS) is a common arrhythmic disorder accounting for about 40-50% of pacemaker implantations. In the United States, about 100,000 SSS-related pacemakers are implanted annually, and prevalence increases markedly after age 65. Tachycardia-bradycardia syndrome (brady-tachy syndrome) accompanies about 40-50% of SSS.

Idiopathic ventricular fibrillation (idiopathic VF) accounts for about 5-10% of cardiac arrest survivors. Premature atrial contractions (PAC) occur in almost all adults and are observed in over 99% on 24-hour Holter. Frequent PACs (>700/day) are an independent predictor of atrial fibrillation.


5. Pathophysiology

The electrophysiological mechanisms of arrhythmias in the I49 category vary by type. The common mechanism of premature depolarizations (PAC, JPC, PVC) is spontaneous depolarization arising in specific cells of the atrial, junctional, or ventricular muscle or conduction system other than the sinoatrial node. This occurs through enhanced automaticity, reentry, or triggered activity (early or delayed afterdepolarizations).

In the case of PVC, left ventricular dysfunction caused by frequent PVCs is the combined result of dyssynchrony, ventricular regurgitation, and neurohormonal activation. The compensatory pause after a PVC is a physiological phenomenon in which sinoatrial node depolarization is reset. Double PVC (R-on-T phenomenon) is a dangerous pattern in which a PVC occurs during the vulnerable period and can induce ventricular fibrillation.

The pathophysiology of sick sinus syndrome is summarized as fibrosis and loss of sinoatrial node cells, reduced expression of HCN4 (If channel) and L-type calcium channels, and a decreased depolarization rate of the sinoatrial node. Shift of the pacemaker site within the sinoatrial node, loss of sinoatrial escape mechanisms, and overdrive suppression, in which premature atrial contractions suppress sinoatrial node automaticity, produce the diverse clinical manifestations of SSS. Autonomic nervous system abnormalities (vagal hyperactivity, cardiac autonomic degeneration) also contribute to SSS.


6. Symptoms

Symptoms of arrhythmias in the I49 category differ by type. The most common symptom of PVC is "a feeling that the heart skips a beat (skipped beat)." This is the perception of the strong normal beat that follows the compensatory pause after a PVC. In addition, some patients experience a strong beat in the neck or chest, anxiety, and shortness of breath. Isolated or infrequent PVCs are mostly asymptomatic, while palpitations, fatigue, and reduced exercise tolerance are more commonly reported with frequent PVCs (>10,000/day).

In sick sinus syndrome (SSS), dizziness, presyncope, and syncope during episodes of bradycardia are the main symptoms. Stokes-Adams attacks — sudden loss of consciousness followed by spontaneous recovery — may occur. Fatigue, exercise intolerance, and cognitive decline are also nonspecific symptoms of SSS. In tachycardia-bradycardia syndrome, episodes of bradycardia and tachycardia (mainly atrial fibrillation) alternate, and a sinus pause follows termination of the tachycardia. Ventricular fibrillation causes immediate loss of consciousness and symptoms of cardiac arrest, the same clinical presentation as cardiac arrest (I46).


7. Signs

On physical examination of PVCs, palpation of the pulse reveals an irregular "skipping" sensation, that is, a pulse deficit observed periodically. In bigeminy the pulse skips every 2 beats, and in trigeminy a deficit appears every 3 beats. On auscultation, a PVC is heard as a strong beat occurring earlier than the preceding normal beat. On the electrocardiogram, a PVC is characterized by a wide, bizarre QRS (≥120ms) without a preceding normal P wave, followed by a full compensatory pause.

In SSS, a persistently slow pulse of 40/min or less, or intermittent loss of the pulse (sinus arrest), is observed. In tachycardia-bradycardia syndrome, sudden abrupt changes in heart rate occur. Various patterns of SSS may be seen on the electrocardiogram: sinus bradycardia, sinus pause (usually 2 seconds or longer), sinoatrial block, and alternation with tachycardia after sinoatrial node dysfunction.


8. Screening

Screening for other cardiac arrhythmias is approached stepwise according to the frequency and severity of symptoms. The 12-lead ECG is the basic test in all patients and evaluates PVC morphology (monomorphic vs. polymorphic), QRS origin, sinus node dysfunction patterns, and so on. 24-48-hour Holter monitoring is essential for calculating PVC frequency and measuring the maximum sinus pause length. When PVC frequency is ≥10-15% of total beats over 24 hours, the likelihood of PVC-induced cardiomyopathy is high and echocardiographic evaluation is required.

When symptoms are infrequent, long-term monitoring is performed with an event monitor or an implantable loop recorder (ILR). When SSS is suspected, the maximum sinus pause length, minimum heart rate, and tachy-brady pattern are analyzed on 24-hour Holter, and the heart rate response during exercise (poor increase in sinus node dysfunction) is evaluated with an exercise stress test. Blood tests are also performed to exclude secondary causes such as pheochromocytoma and hyperthyroidism.


9. Diagnosis

The diagnosis of PVC is confirmed on ECG by a premature wide QRS (≥120ms) without a preceding P wave and a full compensatory pause. Morphological analysis of PVCs (monomorphic: same origin; polymorphic: multiple origins) influences the treatment plan. The site of PVC origin can be estimated from 12-lead ECG morphology (right ventricular outflow tract, left ventricular papillary muscle, mitral annulus, etc.), and the exact site of origin is confirmed by 3D mapping during catheter ablation.

For the diagnosis of SSS, criteria of a sinus pause ≥2 seconds (with symptoms) or ≥3 seconds (asymptomatic) on 24-hour Holter are applied. On electrophysiology study, a corrected sinus node recovery time (CSNRT) ≥550ms supports SSS. In the diagnosis of idiopathic ventricular fibrillation, cardiac MRI, genetic testing, and drug provocation testing (sodium channel blocker administration → provocation of the Brugada pattern) are important for differentiation. Cardiac MRI is used to evaluate structural substrates such as ARVC and myocardial fibrosis.


10. Treatment

Treatment of other cardiac arrhythmias is individualized according to the type of arrhythmia, symptoms, and underlying heart disease.

Treatment of PVC differs depending on the presence or absence of structural heart disease. When there is no structural heart disease, PVC frequency is low, and the patient is asymptomatic, no treatment is needed and avoidance of triggers (caffeine, alcohol, stress) is recommended. For symptomatic PVCs, beta-blockers or calcium channel blockers (verapamil, diltiazem) are the first-line drugs. When PVC frequency is >10%, symptoms persist, or PVC-induced cardiomyopathy is suspected, catheter ablation is highly effective, with success rates reaching 80-95%.

The definitive treatment of SSS is permanent pacemaker implantation. It is a Class I indication in SSS accompanied by symptoms (syncope, recurrent dizziness), and if contributing drugs are present, their discontinuation is attempted first. A single-chamber (AAI or VVI) or dual-chamber (DDD) pacemaker is selected, and when tachycardia-bradycardia syndrome is present, a pacemaker with built-in antiarrhythmic function (DDDR with mode switching) is useful. In idiopathic ventricular fibrillation, secondary-prevention ICD implantation is standard, and for ablatable triggering PVCs (especially of pulmonary vein or papillary muscle origin), catheter ablation is performed as additional treatment.


11. Prognosis

The prognosis of arrhythmias in the I49 category varies greatly with type and underlying heart disease. Isolated PVCs without structural heart disease generally have a good prognosis, with no increase in cardiovascular mortality risk on long-term observation. However, when PVC burden is >15%, PVC-induced cardiomyopathy develops in about 10-15%, and left ventricular function often normalizes when PVCs are eliminated by catheter ablation.

In SSS, symptoms are effectively controlled with pacemaker implantation. After pacemaker implantation, the syncope recurrence rate decreases markedly to less than 5%. In SSS accompanied by tachycardia-bradycardia syndrome, anticoagulation is needed to prevent atrial fibrillation-related stroke, and in this case prognosis is more affected by atrial fibrillation-related complications. In idiopathic ventricular fibrillation with an ICD implanted, the rate of appropriate ICD therapy (shocks) is about 10-15% per year, and early defibrillation by the ICD prevents sudden cardiac death.


12. Prevention

Prevention of other cardiac arrhythmias is approached differently by cause. For PVC prevention, management of triggers is important. Excessive caffeine (coffee, energy drinks) intake, alcohol, smoking, sleep deprivation, and stress increase PVCs and should be limited. Hypokalemia and hypomagnesemia are common triggers of PVCs and ventricular fibrillation, so electrolyte abnormalities are corrected and an appropriate diet is maintained.

Prevention of SSS consists of slowing progression through active treatment of the underlying disease. Care is taken not to use drugs that worsen sinus node dysfunction (beta-blockers, calcium channel blockers, digoxin, amiodarone) more than necessary. Especially in patients with underlying heart disease, polypharmacy interactions must be checked when prescribing QT-prolonging drugs (some antibiotics, antipsychotics, antihistamines, etc.). In families with a predisposition to inherited arrhythmias, asymptomatic carriers are detected early through genetic testing and ECG screening, and appropriate education and follow-up are provided.


13. References

  1. Kusumoto FM, Calkins H, Boehmer J, et al. JCS/JHRS 2024 Guideline Focused Update on Management of Cardiac Arrhythmias. J Arrhythm. 2024;40(3):396-476. DOI: 10.1002/joa3.13023. PMID: 38932978.

  2. Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2015;36(41):2793-2867. DOI: 10.1093/eurheartj/ehv316. PMID: 26320108.

  3. Latchamsetty R, Yokokawa M, Morady F, et al. Multicenter Outcomes for Catheter Ablation of Idiopathic Premature Ventricular Complexes. JACC Clin Electrophysiol. 2015;1(3):116-123. DOI: 10.1016/j.jacep.2015.04.005. PMID: 29759367.

  4. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324(12):781-788. DOI: 10.1056/NEJM199103213241201. PMID: 1900101.

  5. Krahn AD, Andrade JG, Dobrev D. Sick Sinus Syndrome. JACC Clin Electrophysiol. 2019;5(12):1329-1345. DOI: 10.1016/j.jacep.2019.08.005. PMID: 31857037.

  6. Safety and Efficacy of an Implantable Cardioverter Defibrillator in Detection and Prevention of Cardiac Arrhythmia — Systematic Review. Bazoukis G, Tse G, Letsas KP, et al. J Cardiovasc Electrophysiol. 2023;34(12):2491-2502. DOI: 10.1111/jce.16099. PMID: 38074043.

  7. Penela D, Acosta J, Aguinaga L, et al. Ablation of Frequent PVC in Patients Meeting Criteria for Primary Prevention ICD Implant: Safety of Withholding the ICD. J Am Coll Cardiol. 2015;65(22):2409-2415. DOI: 10.1016/j.jacc.2015.04.008. PMID: 26046729.

  8. Bun SS, Latcu DG, Marchlinski F, Saoudi N. Atrial flutter: more than just one of a kind. Eur Heart J. 2015;36(35):2356-2363. DOI: 10.1093/eurheartj/ehv118. PMID: 25888007.

  9. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease. Circulation. 2014;129(23):e521-e643. DOI: 10.1161/CIR.0000000000000031. PMID: 24589853.

  10. Sheldon R, Grubb BP, Olshansky B, et al. 2015 Heart Rhythm Society Expert Consensus Statement on the Diagnosis and Treatment of Postural Tachycardia Syndrome, Inappropriate Sinus Tachycardia, and Vasovagal Syncope. Heart Rhythm. 2015;12(6):e41-e63. DOI: 10.1016/j.hrthm.2015.03.029. PMID: 25980576.